Evaluation of vitamin-producing and immunomodulatory lactic acid bacteria as a potential co-adjuvant for cancer therapy in a mouse model by Levit, Romina et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/jam.14918
 This article is protected by copyright. All rights reserved
1
2 MS. ROMINA  LEVIT (Orcid ID : 0000-0002-6398-2510)
3 MR. JEAN GUY  LEBLANC (Orcid ID : 0000-0002-4634-8630)
4
5
6 Article type      : Original Article
7
8
9 Evaluation of vitamin-producing and immunomodulatory lactic 
10 acid bacteria as a potential co-adjuvant for cancer therapy in a 
11 mouse model
12
13 Romina Levit Ph.D.1, Graciela Savoy de Giori Ph.D.1,2, Alejandra de Moreno de LeBlanc 
14 Ph.D. 1,†,#, Jean Guy LeBlanc Ph.D. 1,†,#
15











This article is protected by copyright. All rights reserved
18 2 Cátedra de Microbiología Superior, Facultad de Bioquímica, Química y Farmacia, 
19 Universidad Nacional de Tucumán. San Miguel de Tucumán, Tucumán, Argentina
20 Running headline: LAB blend as co-adjuvant for cancer
21 #Corresponding authors
22 Dr. Jean Guy LeBlanc. E-mail: leblanc@cerela.org.ar / leblancjeanguy@gmail.com
23 Dr. Alejandra de Moreno de LeBlanc. E-mail: demoreno@cerela.org.ar
24 † Participated equally in this work
25 Abstract
26 Aims: To evaluate a mixture of selected lactic acid bacteria (LAB) (a riboflavin-producer, a 
27 folate-producer and an immunomodulatory strain) as co-adjuvant for 5-fluorouracil (5-FU) 
28 chemotherapy in cell culture and using a 4T1 cell animal model of breast cancer. Methods 
29 and results: The viability of Caco-2 cells exposed to 5-FU and/or LAB was analyzed. Mice 
30 bearing breast tumor were treated with 5-FU and/or LAB. Tumor growth was measured. 
31 Intestinal mucositis (IM) was evaluated in small intestine; hematological parameters and 
32 plasma cytokines were determined. The bacterial mixture did not negatively affect the 
33 cytotoxic activity of 5-FU on Caco-2 cells.  The LAB mixture attenuated the IM and 
34 prevented blood cell decreases associated to 5-FU treatment. Mice that received 5-FU and 
35 LAB mixture decreased tumor growth and showed modulation of systemic cytokines 
36 modified by both tumor growth and 5-FU treatment. The LAB mixture by itself delayed tumor 
37 growth. Conclusions: The mixture of selected LAB was able to reduce the side-effects 
38 associated with chemotherapy without affecting its primary anti-tumor activity. Significance 
39 and impact of the study: This bacterial mixture could prevent the interruption of 
40 conventional oncologic therapies by reducing undesirable side-effects. In addition, this blend 
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44 Introduction
45 Breast cancer (BC) is the most deadly cancer in women and treatment options depend on 
46 the subtype of the disease and include endocrine treatment, targeted therapy and 
47 chemotherapy (Campos-Parra et al. 2018). Approximately 60% of patients with early breast 
48 cancer are treated with chemotherapeutic agents such as 5-fluorouracil (5-FU) or 
49 cyclophosphamide, which can lead to gastrointestinal toxicity (Agrawal et al. 2017). In this 
50 sense, intestinal mucositis (IM) continues to be one of the most frequent side-effects that 
51 decreases the patients’ quality of life and can also lead to the interruption of the anti-
52 neoplastic therapy (Chang et al. 2018). 
53 5-FU acts by inhibiting the enzyme thymidylate synthase and by incorporating its metabolites 
54 into DNA and RNA thereby suppressing the proliferation of cancer cells. However, other 
55 cells of rapid proliferation such as those of the gastrointestinal tract are also susceptible to 
56 this agent and can be affected resulting in IM (Trindade et al. 2018). Patients suffering from 
57 IM can experience abdominal pain, nausea, vomiting, diarrhea, weight loss, mal-absorption 
58 of nutrients and in severe cases the destruction of the intestinal barrier (Chen et al. 2017a). 
59 Furthermore, to date there is little progress in the development of any preventive therapy or 
60 treatment for IM, therefore it is necessary to explore new strategies that may accompany 
61 oncological therapies and attenuate this disorder. It is also indispensable to find 
62 complementary treatments that do not interfere with the anti-tumor effect of chemotherapy 
63 agents and be safe for the host under these special conditions. It was also reported that 
64 patients under systemic chemotherapy frequently require dietary supplements (especially 
65 vitamins and minerals) in order to improve their nutritional state and quality of life (Drozdoff 
66 et al. 2018; Luo and Asher 2018). 
67 Probiotics are defined as live microorganisms that when administered in adequate amounts 
68 confer health benefits to the host (WHO 2002). The effect of lactic acid bacteria (LAB), the 
69 microorganisms most commonly used as probiotics, on different intestinal disorders has 
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71 may be associated with different mechanisms including the supply of vitamins (Levit et al. 
72 2018b). In this sense, in a previous study we showed that the administration of a riboflavin-
73 overproducing strain Lactobacillus (Lact.) plantarum CRL 2130, prevented IM in mice (Levit 
74 et al. 2018c). In addition, we recently reported the benefits associated with the 
75 administration of Streptococcus (Strep.) thermophilus CRL 808, a strain that produces folate, 
76 in mice with chemically-induced IM (Levit et al. 2018a).
77 The modulation of the host’s immune response has also been suggested as a beneficial 
78 mechanism exerted by probiotic LAB. Previous studies demonstrated the 
79 immunomodulatory properties of Strep. thermophilus CRL 807 (del Carmen et al. 2014).
80 Additionally, the administration of a mixture of LAB strains with anti-inflammatory properties 
81 exerted through different mechanisms can enhance the individual effect of each strain by 
82 itself. In this sense, we reported that the administration of a blend of three selected LAB 
83 (Lact. plantarum CRL 2130, Strep. thermophilus CRL 808 and Strep. thermophilus CRL 807) 
84 to mice with chronic colitis induced by 2,4,6-trinitrobenzene sulfonic acid did not affect the 
85 primary treatment with an anti-inflammatory drug and also prevented the side-effects of this 
86 therapy (Levit et al. 2019). 
87 Therefore, the aim of this study was to evaluate the effect of a LAB mixture composed by a 
88 riboflavin-overproducing strain (Lact. plantarum CRL 2130), a folate-producing strain (Strep. 
89 thermophilus CRL 808) and an immunomodulatory strain (Strep. thermophilus CRL 807) on 
90 the antiproliferative activity of 5-FU against Caco-2 cells and on the chemotherapy side-
91 effects (IM) in mice with breast cancer. The potential benefit of the LAB mixture against 
92 breast cancer growth was also analyzed.
93
94 Materials and Methods
95 Lactic acid bacteria preparation
96 Streptococcus (Strep.) thermophilus CRL 807 (isolated from artisanal yogurt) was selected 
97 from previous studies due to its immunomodulatory properties (del Carmen et al. 2014), 
98 Lactobacillus (Lact.) plantarum CRL 2130 (isolated from sugar cane residues) a riboflavin-
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100 folate-producing strain, were selected due to their anti-inflammatory properties (Levit et al. 
101 2018c; Levit et al. 2018a).
102 All the strains used in this study are from CERELA Culture Collection (Tucumán, Argentina). 
103 They were grown for 16 h at 37ºC without agitation in De Man, Rogosa and Sharpe (MRS, 
104 Britania, Buenos Aires, Argentina) broth for lactobacilli or LAPTg containing (w/v) 1.5% 
105 peptone, 1% tryptone, 1% yeast extract, 1% glucose and 0.1% Tween 80 for streptococci. 
106 The vitamin-producing strains were then inoculated at 4% (v/v) in 10 ml of riboflavin-free 
107 culture medium (Riboflavin Assay Medium) for Lact. plantarum CRL 2130 or folate-free 
108 culture medium (Folic Acid Casei Medium, FACM) for Strep. thermophilus CRL 808, both 
109 from Difco, Becton, Dickinson, and Co. (Sparks, Maryland, USA) and incubated without 
110 agitation at 37ºC for 16 h. The immunomodulatory strain Strep. thermophilus CRL 807 was 
111 also inoculated at 4% (v/v) in 10 ml of LAPTg and incubated without agitation at 37ºC for 16 
112 h.
113 For bacterial suspensions the cells were washed and concentrated 10 times in sterile saline 
114 solution (0.85% w/v NaCl). The suspensions for animal feeding (100 µl) contained 8 ± 2 x 
115 108 CFU ml-1 of each strain (Lact. plantarum CRL 2130, Strep. thermophilus CRL 808 and 
116 Strep. thermophilus CRL 807). Fresh cultures were daily prepared for animal feeding. Before 
117 administration to the animals, the OD580nm was determined to estimate the CFU based on 
118 a previously established standard curve. In addition, before being administered, a sample 
119 was plated to confirm the average CFU that was effectively administered every day.
120
121 Animals
122 Female BALB/c mice weighing 18-22 g were provided by the inbred animal facility of 
123 CERELA. Animals were kept in cages and were maintained under a 12 h light/ dark cycle at 
124 18-20ºC, with water and conventional rodent food available ad libitum. Animal studies were 
125 performed in accordance with the current laws of Argentina and international organizations 
126 for the use of experimental animals. The experimental protocols were approved by the 
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129
130 Induction of intestinal mucositis and treatment protocols
131 Six weeks old mice were randomly distributed into three groups (n=5). Mock group was 
132 injected intraperitoneally (i.p.) and orally administered with saline (0.85% NaCl, w/v) once 
133 and twice a day respectively. IM was induced in the rest of the groups by daily i.p. injections 
134 of 5-FU (50 mg kg-1 body weight) for six consecutive days. These animals were subdivided 
135 into two groups and orally administered with 100 µl of LAB mixture containing 8 ± 2 x 108 
136 CFU ml-1 of each strain (5-FU + MIX LAB group) or saline (5-FU + Saline group) twice a day 
137 for six consecutive days by using a syringe with a gavage needle.
138 To evaluate the disease severity, the body weight and the feces from each mouse were 
139 checked daily by a single observer. The stool consistency was classified according to a pre-
140 established score system from zero to three according to the absence of diarrhea or its 
141 severity degree (Huang et al. 2009): a score of zero indicated normal stool, one indicated 
142 slight diarrhea, two moderate diarrhea, and three watery diarrhea. Mice were euthanized 20 
143 hours after the last bacterial administration. Animals were i.p. anesthetized with a mixture of 
144 ketamine hydrochloride (Laboratorios König S.A., Buenos Aires, Argentina) 100 µg g-1 body 
145 weight and xylazine at 2% (Bayer, Leverkusen, Renania del Norte- Westfalia, Germany) 5 
146 µg g-1 body weight. Blood samples were obtained by cardiac puncture and the serum was 
147 stored at -80°C; small intestines were removed and segments of jejunum from each animal 
148 were fixed in formaldehyde solution (10% v/v in PBS) for histological evaluation.
149
150 Cell culture, treatments and assays
151 Caco-2 human colorectal adenocarcinoma cells (ATCC HTB37) were maintained in 
152 Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Gran Island, NY, USA) with 10% fetal 
153 bovine serum (FBS, NATOCOR, Córdoba, Argentina) penicillin, streptomycin, and 
154 amphotericin B (Gibco) in a humidified incubator at 37ºC with an atmosphere of 5% CO2.
155 Cells from passage 57 were seeded at 5 x 104 cells ml-1 in a 96-wells culture plate. After 24 
156 h the medium was replaced with fresh DMEM without antibiotics and the LAB mixture (Lact. 
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158 added in a cell:bacteria ratio of 1:103 (with the same proportion for each strain). After 
159 incubation for 24 h, the cells were treated with 5-FU (100 g ml-1) for 24 h.
160 Cell viability was evaluated by MTT (3-[4,5-dymethilthiazol-2-yl]-2,5-diphenyl-tetrazolium 
161 bromide) assay. Gentamicin (20 mg l-1) was added to kill bacteria and then the MTT (Sigma- 
162 Aldrich, St. Louis, MO, USA) solution at a concentration of 5 mg ml-1 in phosphate buffered 
163 solution (PBS) was added to each well and incubated at 37ºC for 4 h. The medium was 
164 discarded and replaced by 100 µl of dimethyl sulfoxide (DMSO) and the absorbance was 
165 recorded at 570 nm using a microplate reader (VersaMax, Molecular Devices, San José, 
166 CA, USA). Results were expressed as a percentage of viability relative to control cells 
167 incubated only with DMEM and without any treatment (100% viability). 
168
169 Tumor induction and treatment protocols
170 Breast tumor bearing mice were used to evaluate the effect of the LAB mixture on the IM 
171 and also on the anti-tumor action of 5-FU. For this experiment, female seven-week old 
172 BALB/c mice were injected subcutaneously with 0.2 ml of  1 x 106 cells ml-1 of 4T1 tumor cell 
173 (purchase from ATCC, American Type Culture Collection, ATCC ® CRL-2539TM) in the 
174 upper right mammary gland following a previously established protocol (Aragón et al. 2015). 
175 A group of mice that received PBS injections was used as control (healthy control).
176 At day 14 after tumor cells’ injection, mice with tumors’ sizes reached 0.4 ± 0.1 cm of 
177 diameter were randomly separated into four groups (n=5): 4T1 + Saline + Saline, 4T1 + 5-
178 FU + Saline, 4T1 + 5-FU + MIX LAB and 4T1 + Saline + MIX LAB. Animals received two 
179 cycles of three i.p. injections of saline or 5-FU (50 mg kg-1 animal weight) day in between 
180 separated by a six day no treatment period. Mice were orally administered with saline or the 
181 LAB mixture daily since the beginning of the first 5-FU cycle (day one of treatments) until the 
182 end of the experiment (day sixteen). 
183 Body weight and size of the tumors were recorded daily by a single observer. The largest 
184 (D) and smallest (d) diameter of the tumor were measured using a caliper, and the volume 
185 (V) was calculated according to the formula V = 0.4 x d2 x D (Aragón et al. 2014). At the end 
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187 xylasine. Blood samples were obtained by cardiac puncture and collected in tubes with 
188 EDTA (ethylene-diamine-tetraacetic acid) solution for hematological analyses and plasma 
189 collection; spleens and tumors were removed and weighed; and small intestines were 
190 dissected for histological evaluation.
191
192 Cytokines evaluation
193 Blood serum or plasma was used to cytokine assay by cytometric bead array (CBA). 
194 Concentrations of Interleukin-10 (IL-10), IL-17, Tumor Necrosis Factor (TNF-α), Interferon- γ 
195 (IFN-γ), IL-6, IL-4 and IL-2 were determined with a CBA mouse inflammation kit or Mouse 
196 Flex Set (BD Bioscience, San Diego, CA, USA) following the manufacturer’s instructions. 
197 Results were expressed as concentration of each cytokines according to the respective 
198 standard.
199
200 Histological assessment of small intestine
201 Intestinal tissues were processed for paraffin embedding using standard methods (Sainte-
202 Marie 1962); sections of 4 µm were cut and stained with hematoxylin and eosin (H&E). 
203 Samples were observed under a light microscope (Carl Zeiss- Axio Scope.A1), and the 
204 images were acquired using a 100x of magnification and analyzed with AxioVision Release 
205 4.8 Software.
206 For morphometric analysis five measurements of villus height and crypt depth were 
207 performed for each mouse and the values were averaged per group. The overall histological 
208 damage was determined by using a histopathological score in which the level of 
209 inflammation is graduated from zero to three based on lesions in the jejunal tissue as was 
210 previously described (Justino et al. 2014).
211
212 Hematological parameters analyses
213 Whole blood samples were used to count total white blood cell (WBC) using a Neubauer 










This article is protected by copyright. All rights reserved
215 stained with Giemsa solution (Biopur, Rosario, Argentina) and analyzed to determine the 
216 percentage of leukocytes’ populations (relative leukocytes formula). 
217                                                                                            
218 Statistical analysis
219 Statistical analyses were performed using MINITAB 15 software (Minitab, State College, PA, 
220 USA). Comparisons between groups were analyzed by ANOVA general linear model 
221 followed by Tukey’s post hoc test and p < 0.05 was consider statistically significant.
222
223 Results
224 Effect of LAB mixture on intestinal mucositis induced by 5-FU
225 Injections of 5-FU were accompained by loss of body weight (data not shown) and the onset 
226 of diarrhea in mice from 5-FU + Saline group compared with mock group (Fig. 1A). The 
227 administration of the LAB mixture (5-FU + MIX LAB group) significantly (p < 0.05) decreased 
228 the diarrhea score when compared to 5-FU + Saline group (Fig. 1A). No significant 
229 differences in body weight loss were observed between the groups treated with 5-FU (data 
230 not shown).
231 The morphometric analysis of the small intestines revealed that 5-FU caused alterations in 
232 the intestinal mucosa of mice from 5-FU + Saline group with significant (p < 0.05) shorter villi 
233 and deeper crypts than the mock group (Fig. 1B). Administration of the LAB mixture (5-FU+ 
234 MIX LAB group) showed a villus height/crypt depth ratio significantly (p < 0.05) higher 
235 compared to 5-FU + Saline group, with values similar to those of the healthy mice (Fig. 1B). 
236 Additionally, histological observations showed that 5-FU caused other histopathological 
237 changes including villus fusion and blunting, loss and atrophy, crypt necrosis, increased 
238 number of inflammatory cells, vacuolization and oedema. Mice from 5-FU + Saline group 
239 had a high inflammation score in comparison to healthy controls (mock group) (Fig. 1C). At 
240 difference, mice from 5-FU + MIX LAB group showed significant (p < 0.05) decreases in the 
241 inflammation score compared to 5-FU + Saline group (Fig. 1C).
242 On the other hand, the cytokine analysis showed significantly (p < 0.05) increased 









This article is protected by copyright. All rights reserved
244 compared to mock group, without significant differences between these two groups in the 
245 other tested cytokines (Fig. 1D). IL-6 and TNF-α levels were significantly (p < 0.05) 
246 decreased in the serum of mice administered the mixture of LAB compared to 5-FU + Saline 
247 group; however the concentration of the pro-inflammatory cytokine IL-6 did not reach the 
248 values of mice from mock group. In addition, the group that received LAB increased 
249 significantly (p < 0.05) the levels of IL-10 compared to 5-FU + Saline group (Fig. 1D). 
250
251 Effect of LAB mixture on viability of Caco-2 cells treated or not with 5-FU
252 In vitro assays showed that the incubation with the mixture of LAB alone (MIX LAB group) 
253 increased Caco-2 cells’ viability compared to cell control without treatment. When the cells 
254 were exposed to the mixture of LAB in combination with 5-FU (MIX LAB group) a significant 
255 (p < 0.05) reduction of viability was observed in comparison to cell control, and a similar 
256 reduction in viability showed cells only treated with 5-FU (Fig. 2). 
257
258 Effect of LAB mixture on the in vivo anti-tumor action of 5-FU
259 Data showed that mice bearing tumor and without any treatment (4T1 + Saline + Saline 
260 group) reached tumor volume values up to 1.53 cm3, with the highest tumor weights at the 
261 end of the experiment (Fig. 3A and 3B). The chemotherapy treatment (4T1 + 5-FU + Saline 
262 group) affected the tumor growth with a significant decrease (p < 0.05) of tumor volumes and 
263 weights when compared to the tumor control group (Fig. 3A and 3B). Likewise, mice that 
264 received 5-FU and the LAB mixture (4T1 + 5-FU + MIX LAB group) showed a significant 
265 decrease (p < 0.05) of tumor volumes and weights compared to the 4T1 + Saline + Saline 
266 group but without significant differences with mice that only received 5-FU (Fig. 3A and 3B). 
267 In addition, the group of mice that received only the mixture of LAB (4T1 + Saline + MIX LAB 
268 group) showed a delay of tumor growth with volumes and weights similar (p > 0.05) to those 
269 observed in mice treated with 5-FU (with or without LAB administration) (Fig. 3A and 3 B). 
270
271 Effect of LAB mixture on intestinal mucositis associated to 5-FU treatment in mice 









This article is protected by copyright. All rights reserved
273 Body weight records did not show significant differences between the healthy control and the 
274 groups of mice bearing tumor and without chemotherapy treatment (4T1 + Saline + Saline 
275 and 4T1 + Saline + MIX LAB groups) (Fig. 4A). However, animals under 5-FU treatment 
276 (4T1+ 5-FU + Saline and 4T1+ 5-FU+ MIX LAB groups) showed significant (p < 0.05) 
277 decreases of body weight which was less pronounced in the group that received the LAB 
278 mixture (Fig. 4A).
279 The microscopic analysis of intestinal tissues showed that 5-FU-treated mice displayed 
280 histological changes in the intestinal mucosa while animals that did not receive 5-FU 
281 (healthy control, 4T1 + Saline + Saline and 4T1 + Saline + MIX LAB groups) maintained the 
282 intestinal architecture (Fig. 4B). Animals from 4T1 + 5-FU + Saline group showed significant 
283 (p < 0.05) shortening of the villi and increase in the crypts depth compared to all the other 
284 test and control groups (Fig. 4B). These animals also showed the highest values for the 
285 intestinal inflammation score with severe inflammatory infiltration, villus deformation and 
286 crypts derangement (Fig. 4C). In contrast, administration of the LAB mixture was effective in 
287 preventing intestinal damages induced by 5-FU in mice from 4T1 + 5-FU + MIX LAB group. 
288 These mice showed values of villus height/crypt depth ratio and inflammation scores 
289 significantly (p < 0.05) increased and decreased, respectively when compared to 4T1 + 5-FU 
290 + Saline group, and without significant differences with the healthy control mice (Fig. 4B and 
291 4C). 
292
293 Effect of LAB mixture and 5-FU treatment on hematological parameters and cytokines 
294 profile in mice bearing breast tumor 
295 The analysis of blood samples from mice bearing breast tumor and without any treatment 
296 (4T1 + Saline + Saline group) showed increased percentages of erythrocytes (43 ± 2%), 
297 number of leukocytes (200,000 ± 100,000 cell ml-1) and modification of the leukocytes 
298 formula with high percentages on polimorphonuclear cells (more than 60%) compared to the 
299 healthy control. These changes are characteristic of the leukemoid reaction associated to 
300 this tumor and were accompanied by splenomegaly (Table 1). Mice bearing tumor that 
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302 percentage of erythrocytes (30 ± 4%) and in the number of leukocytes (1,600 ± 500 cell ml-
303 1), a leukocytic formula with predominance of lymphocytes (more than 70%) and a decrease 
304 in the spleen weight/body weight ratio in comparison to tumor control mice (4T1 + Saline + 
305 Saline group) (Table 1). However, these mice decreased significantly (p < 0.05) the 
306 percentage of red blood cells, the number of leukocytes and the size of the spleen when 
307 compared to healthy control group. Mice that received 5-FU and the LAB mixture (4T1 + 5-
308 FU + MIX LAB group) showed similar results than those only treated with 5-FU; however, 
309 some mice increased red and white blood cells and the spleen/body weight ratio to values 
310 closed to the healthy mice (Table 1). At difference, mice bearing tumor that received the LAB 
311 mixture without chemotherapy (4T1 + Saline + MIX LAB group) decreased significantly the 
312 number of leukocytes (15,000 ± 10,000 cell ml-1) with a leukocyte formula similar to healthy 
313 mice (predominance of lymphocytes) and decreased spleen weight/body weight ratio in 
314 more than 50% of the mice, compared to the tumor control group (4T1 + Saline + Saline 
315 group), but without reach the values of healthy mice in most of the animals (Table 1).
316 Determinations of plasma cytokines concentrations showed that the levels of TNF-α were 
317 significantly (p < 0.05) higher in mice bearing tumor that did not receive any treatment (27 ± 
318 5 pg ml-1 for 4T1 + Saline + Saline group) and they were maintained in mice received 5-FU 
319 (29 ± 2 pg ml-1 for 4T1 + 5-FU + Saline group) in comparison with animals from healthy 
320 control group (9 ± 3 pg ml-1) (Fig. 5). Administration of LAB mixture (4T1 + Saline + MIX LAB 
321 and 4T1+ 5-FU+ MIX LAB groups) significantly (p < 0.05) decreased the levels of this 
322 cytokine (15 ± 3 and 21 ± 2 pg ml-1, respectively), by they were maintained significantly (p < 
323 0.05) increased compared to healthy mice (Fig.5). IL-10 levels were significantly (p < 0.05) 
324 increased in all the test groups compared to healthy mice (Fig. 5). Results also showed that 
325 5-FU treatment increased concentrations of IL-6 (253 ± 81 pg ml-1), IFN-γ (11 ± 5 pg ml-1) 
326 and IL-17 (35 ± 3 pg ml-1) in mice bearing tumor (4T1 + 5-FU + Saline group) when 
327 compared with animals from tumor control group (6 ± 2.5 5 ± 2 and 5 ± 1 pg ml-1 for IL- 6, 
328 INF-γ and IL- 17, respectively) (Fig. 5). A significant (p < 0.05) decrease in IL- 6 levels (100 
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330 mixture (4T1+ 5-FU+ MIX LAB group) (Fig. 5). No significant differences were detected for 
331 the other tested cytokines when compared both groups that received 5-FU treatment.
332
333 Discussion
334 Chemotherapy is one of the most widely used and effective treatments in the clinical practice 
335 for a variety of cancers. However, it produces adverse effects in patients, and among them 
336 one of the most common is IM (Kato et al. 2015). For this reason, the search for adjuvant 
337 agents that minimize the toxicity of oncological drugs without reducing their anti-tumor 
338 efficacy has become an important issue (Chen et al. 2017b; Mi et al. 2017). As stated 
339 before, the intake of vitamin and mineral supplements is very common among patients under 
340 chemotherapy and this could be related to the associated gastrointestinal problems and the 
341 need to prevent dietary deficiencies and improve the quality of life. However, it is important 
342 to be sure that these supplements do not interfere with the primary anti-cancer treatments.
343 In our study the injections of 5-FU were accompanied by loss of body weight and the onset 
344 of diarrhea (Fig. 1A), similar to previous results using the same drug (Kato et al. 2017; Oh et 
345 al. 2017; Tang et al. 2017). Additionally, signs of inflammatory damage in the intestines (Fig. 
346 1B and 1C) accompanied by levels of serum IL-6 and TNF-α significantly increased (Fig. 1D) 
347 were observed, demonstrating an inflammatory state in these mice.
348 Considering the intake of vitamins by patients under chemotherapy, we previously evaluated 
349 the administration of vitamin-producing bacteria to mice with chemically induced IM and it 
350 was observed that both the administration of a riboflavin-producing strain (Lact. plantarum 
351 CRL 2130) as well as a folate-producing strain (Strep. thermophilus CRL 808) exerted anti-
352 inflammatory effects with attenuation of the IM (Levit et al. 2018a; Levit et al. 2018c). With 
353 the aim of enhancing this beneficial effect, a mixture of LAB that can act through different 
354 mechanisms against this inflammatory pathology was used in the present study. The LAB 
355 mixture consisted of both mentioned vitamin-producing strains and Strep. thermophilus CRL 
356 807, selected for its immunmodulatory properties. In the present study the LAB mixture 
357 (Lact. plantarum CRL 2130, Strep. thermophilus CRL 808 and Strep. thermophilus CRL 807) 
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359 damages at intestinal structure level (Fig. 1B and 1C), reduction of diarrhea degree (Fig. 1A) 
360 and decreased serum concentrations of IL-6 and TNF-α; in addition with increased levels of 
361 the regulatory cytokine IL-10 (Fig. 1D). This observation, different to the results obtained 
362 previously with the vitamin-producing strains (Levit et al. 2018c; Levit et al. 2018a) could be 
363 associated to the immunomodulatory properties of Strep. thermophilus CRL 807, as was 
364 demonstrated previously in other mouse models (del Carmen et al. 2014). According to the 
365 results we can suggest that bacteria in the mixture acted synergistically against IM since the 
366 overall effect was better than when each strain was administered individually as was 
367 observed previously for the riboflavin and the folate-producing strains (Levit et al. 2018a; 
368 Levit et al. 2018c). 
369 Considering the importance that the adjuvant agents must not interfere with the anti-tumor 
370 activity of the chemotherapy, the effects of the LAB mixture were studied by in vitro assays  
371 using the human colon cancer Caco-2 cells treated with 5-FU. When the cells were exposed 
372 to the LAB mixture in combination with 5-FU a significant reduction of viability was observed 
373 in comparison to cell control, whereas with the 5-FU treatment alone a similar reduction in 
374 viability was observed (Fig. 2). This results clearly demonstrated that our LAB mixture did 
375 not affect the treatment efficiency of 5-FU against colon cancer cells in culture. These results 
376 differ from others in which certain LAB were associated to concentration- and time-
377 dependent anti-proliferative effects against Caco-2 cells (Tiptiri-Kourpeti et al. 2016), and 
378 also differ with the results obtained previously with the riboflavin and the folate-producing 
379 strains. In previous studies the vitamin-producing strains showed an anti-proliferative effect 
380 in vitro on Caco-2 cells, which was enhanced by the combination with 5-FU (Levit et al. 
381 2018a; Levit et al. 2018c). The results obtained in the present study can be associated to the 
382 presence of Strep. thermophilus CRL 807 in the mixture of LAB. Since  Caco-2 cell culture 
383 does not allow to analyse the influence of the bacteria on the immune response (the most 
384 important benefit associated to Strep. thermophilus CRL 807), the effects of the LAB mixture 
385 were tested using an in vivo cancer model under treatment with 5-FU. 
386 The antitumoral and antimetastatic activity of LAB was previously reported in a breast tumor 
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388 Aragón et al. 2015). In the present work, the bacteria were not administered in a food matrix, 
389 they were administered as oral suspension and accompanied a chemotherapy treatment. 
390 The results obtained showed that the LAB mixture maintained the effect of 5-FU (decrease 
391 of tumor volumes and weights) (Fig. 3A and 3B). In addition, the LAB mixture by itself 
392 showed a potential anti-cancer effect as was observed by the reduction of tumor volumes 
393 and weights in mice that received these LAB without other treatment (Fig. 3A and 3B). This 
394 effect was also observed on the leukemoid reaction associated to the tumor model, similar to 
395 the results reported with a probiotic fermented milk (Aragón et al. 2014). Mice received the 
396 mixture of LAB decreased the  percentage of erythrocytes, the number of leukocytes, 
397 modified the leukocyte relative formula and decreased spleen weight/body weight ratio to 
398 values closed to those of healthy control mice (Table 1). The analysis of plasma cytokines 
399 revealed that mice from tumor control group increased TNF-α levels (Fig. 5) as was 
400 observed in other previous work (Aragón et al. 2014). Interestingly, the group that received 
401 only the mixture of LAB decreased the levels of this cytokine demonstrating a potential of 
402 modulate the immune response against the tumor (Fig. 5), different to the effect associated 
403 to the anti-cancer drug used in the present study.
404 In addition the LAB mixture was also analyzed regarding the side effects associated to 5-FU 
405 treatment in mice bearing breast tumor.
406 It has been reported that the administration of probiotic LAB prevented IM induced by 
407 FOLFOX (5- FU, leucovorin, and oxaliplatin) in colorectal cancer bearing mice and by 5-FU 
408 + oxaliplatin in rats with colon cancer, without affecting the anti-tumor effect of the drugs (Mi 
409 et al. 2017; Chang et al. 2018). In our study the administration of 5-FU reduced breast tumor 
410 growth; however also produced IM. Similarly to the results obtained in healthy mice, in the 
411 tumor model, the intestinal damages and some hematological disorders induced by the 
412 chemotherapy with 5-FU were mitigated in the animals that received the LAB mixture (Fig. 
413 4A, 4B and 4C and Table 1). The chemotherapy treatment was not associated to decrease 
414 of TNF-α (Fig. 5), which could be explained for the inflammation induced for this treatment, 
415 as was explained in the model of IM without tumor. In addition, increased concentration of 
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417 alone, but not in those that received the LAB mixture as co-adjuvant. This last group also 
418 decreased the plasma levels of TNF-α, demonstrating again the anti-inflammatory potential 
419 of the bacterial mixture (Fig 5).
420 In conclusion our study demonstrates that the administration of a mixture of selected LAB 
421 with anti-inflammatory properties exerted by different mechanisms was able to reduce the 
422 severity of the IM associated with the 5-FU chemotherapy without affecting the anti-tumor 
423 activity of this drug. In addition, this blend would provide essential nutrients (vitamins) to 
424 oncology patients. Furthermore the designed LAB mixture induced by itself a delay of the 
425 tumor growth, increasing its potential to be used as co-adjuvant of conventional anti-tumor 
426 treatments. These findings highlight the importance of the adequate selection of LAB strains 
427 with beneficial properties in order to design mixtures that are more effective than using 
428 individual strains and enhance their potential for co-adjuvant use against cancer. However, 
429 further studies on the dietary supplement intake in cancer patients are important in order to 
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558 Figure 1. LAB mixture decreased intestinal mucositis induced by 5-FU. (A) The severity 
559 of diarrhea was scored from zero to three on day six. (B) Histological analysis of villus height 
560 and crypt depth was performed in small intestine samples. (C) The level of inflammation in 
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562 concentrations of serum cytokines were determined by cytometric bead array. Data are 
563 presented as mean ± SD of five mice. For A, B and C:  ‡ and * mean significant differences 
564 (p < 0.05) compared with mock group and 5-FU + Saline group, respectively. For D different 
565 letters (a-c) show significant statistic differences (p < 0.05). IL-10 (white), IL-17 (black), TNF-
566 α (white with diagonal lines), INF-γ (light grey with horizontal lines), IL-6 (dark grey), IL-4 
567 (dotted white) and IL-2 (dotted black)
568
569 Figure 2. LAB mixture affected the viability of Caco-2 cells treated with 5-FU. Viability 
570 of Caco-2 cells was measured by MTT assay after the incubation with the LAB mixture in 
571 presence or absence of 5-FU. Results are expressed as a percentage relative to control 
572 cells without treatment (100% viability). Data are presented as mean ± SD from an 
573 experiment conducted in triplicate. Data with different letters (a-d) significantly differ (p < 
574 0.05). Control (white), MIX LAB (black)
575
576 Figure 3. Administration of LAB mixture did not affect the anti-tumor action of 5-FU. 
577 (A) Tumor volume (cm3) changes during the experiment are shown for each mouse with the 
578 tendency line for each group; the statistical analysis is presented for the last time point. (    ) 
579 4T1 + Saline + Saline, (    ) 4T1+ 5-FU + Saline, (    ) 4T1+ 5-FU + MIX LAB, (   ) 4T1 + 
580 Saline + MIX LAB. (B) Tumors weights were evaluated at the end of the experiment. Values 
581 are expressed as mean ± SD (n=5). Different letters (a-b) indicate significant difference (p < 
582 0.05)
583
584 Figure 4. Administration of LAB mixture relieved intestinal mucositis associated to 
585 the chemotherapy treatment in mice bearing breast tumor. (A) Variation of body weight 
586 through the experiment was expressed related to initial body weight (100%). (    ) 4T1 + 
587 Saline + Saline, (    ) 4T1 + 5-FU + Saline, (   ) 4T1 + 5-FU + MIX LAB, (   ) 4T1 + Saline + 
588 MIX LAB, (   ) healthy control. (B) Morphometric analysis of intestinal villus height and crypt 
589 depth. (C) Histopathological evaluation performed in jejunum samples. Data are expressed 
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591
592 Figure 5. Administration of LAB mixture reduced inflammatory cytokines in mice 
593 bearing breast tumor with or without chemotherapy treatment. Cytokines concentration 
594 was determined in plasma samples by cytometric bead array. Data for each bar correspond 
595 to mean ± SD (n=5). Different letters (a-c) indicate significant difference (p < 0.05). IL-6 
596 (white), IL-10 (black), TNF-α (white with diagonal lines), INF-γ (light grey with horizontal 























Percentage of erythrocytes, white blood cell count and leukocyte formula were performed on whole blood samples  
* Values are expressed as mean ± SD 
† Results show the range of data for each group 
‡ Results show the polimorphonuclear and lymphocytes percentages (range of data for each group) 
 Erythrocytes (%) * Leukocytes (cell ml-1) †  Leukocyte formula ‡  
Ratio 
Spleen/body (g g-1) § 
   Lymphocytes (%) Neutrophils (%)  
Healthy control 37 ± 1 a 4,700 ± 200  >70  10-30  0.9 ± 0.3 a 
4T1+ Saline+ Saline 43 ± 2 b 200,000 ± 100,000 10-30  >60  3.9 ± 0.7 b 
4T1+ 5-FU+ Saline 30 ± 4 c 1,600 ± 500 >70  10-35  0.4 ± 0.3 c 
4T1+ 5-FU+ MIX LAB 31 ± 2 c 2,200 ± 1,200 >50  20-50  0.7 ± 0.1 a 
4T1+ Saline+ MIX LAB 41 ± 2 b 15,000 ± 10,000 20-60  40-70  2.4 ± 0.9 b 
 
 
§ The spleen was extracted, weighed and the value was expressed as a function of body weight. Results are expressed as 
mean ± SD 
Data correspond to n=5 mice per group. Different letters (a-c) show significant difference (p < 0.05) 
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